{"id":5688,"date":"2024-04-17T08:05:18","date_gmt":"2024-04-17T13:05:18","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5688"},"modified":"2025-06-27T11:19:59","modified_gmt":"2025-06-27T16:19:59","slug":"nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/","title":{"rendered":"Terap\u00e9utica con nanoscopios se presentar\u00e1 en el Congreso Mundial de Medicamentos Hu\u00e9rfanos 2024"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">17 de abril de 2024<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, Director General y\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, PhD, presidente y director cient\u00edfico de Nanoscope Therapeutics, presentar\u00e1 y participar\u00e1 en un panel de discusi\u00f3n en el Congreso Mundial de Medicamentos Hu\u00e9rfanos 2024, que tendr\u00e1 lugar desde\u00a0<span class=\"xn-chron\">23-25 de abril de 2024<\/span>\u00a0en\u00a0<span class=\"xn-location\">Boston, Massachusetts<\/span>. Los detalles de las presentaciones son los siguientes:<\/p>\n<p><b>T\u00edtulo:\u00a0<\/b>Revolucionando la restauraci\u00f3n de la visi\u00f3n: terapia optogen\u00e9tica independiente de mutaciones para enfermedades hereditarias de la retina<br class=\"dnr\" \/><b>T\u00edtulo de la sesi\u00f3n:\u00a0\u00a0<\/b>Lanzamiento y socio<b><br class=\"dnr\" \/>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">martes 23 de abril<\/span><sup>tercero<br class=\"dnr\" \/><\/sup><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">3:00 pm. est<\/span>, Sala C, Teatro 4<br class=\"dnr\" \/><b>Presentador:\u00a0<\/b><span class=\"xn-person\">Sulagna Bhattacharya<\/span>, Director ejecutivo<\/p>\n<p>La Sra. Bhattacharya abordar\u00e1 el desarrollo y la aplicaci\u00f3n de la plataforma Multi-Characteristic Opsin (MCO) de Nanoscope para el tratamiento restaurador e independiente de mutaciones de m\u00faltiples enfermedades raras dentro del \u00e1mbito de la distrofia retiniana hereditaria (IRD). La Sra. Bhattacharya tambi\u00e9n participar\u00e1 en una mesa redonda junto con el Director Cient\u00edfico de Nanoscope.,\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, Doctor. Los detalles del panel son los siguientes:<\/p>\n<p><b>T\u00edtulo:\u00a0<\/b>Rompiendo barreras: acceso a la terapia g\u00e9nica para pacientes neurodegenerativos<br class=\"dnr\" \/><b>T\u00edtulo de la sesi\u00f3n<\/b>: Mundo de defensa de las enfermedades raras<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">martes 23 de abril<\/span><sup>tercero<br class=\"dnr\" \/><\/sup><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">15:20. est<\/span>, Sala C, Teatro 1<br class=\"dnr\" \/><b>Panelistas:\u00a0<\/b><span class=\"xn-person\">Sulagna Bhattacharya<\/span>, Director General y\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, PhD, director cient\u00edfico<\/p>\n<p>El panel abordar\u00e1 los obst\u00e1culos que enfrentan los desarrolladores de terapias g\u00e9nicas para tratar enfermedades neurodegenerativas raras. Entre estas enfermedades se incluyen las enfermedades degenerativas de la retina, en cuya soluci\u00f3n se centra Nanoscope. En concreto, la Sra. Bhattacharya y el Dr. Mohanty compartir\u00e1n las experiencias y los desaf\u00edos encontrados durante el desarrollo del principal f\u00e1rmaco de Nanoscope, MCO-010, para el tratamiento de la retinosis pigmentaria independiente de mutaciones, y c\u00f3mo estas terapias gen\u00e9ticas independientes pueden ampliar el acceso a los pacientes.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen que restauran la visi\u00f3n para millones de pacientes ciegos por enfermedades retinianas hereditarias para las que no existe cura. El principal f\u00e1rmaco de la compa\u00f1\u00eda, MCO-010, complet\u00f3 recientemente la fase RESTORE.\u00a0<span class=\"xn-money\">2b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinitis pigmentosa (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4142945-1&h=4102903919&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4142945-1&h=816220308&u=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la GA debida a la DMAE.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:Nanoscope@argotpartners.com\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscope@argotpartners.com<\/a><\/p>\n<div>\n<div class=\"divOverflow\">\n<div class=\"table-responsive\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0April 17, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sulagna Bhattacharya, Chief Executive Officer and\u00a0Samarendra Mohanty, PhD, President and Chief Scientific Officer of Nanoscope Therapeutics, will present and participate in a panel discussion at the\u00a0World Orphan Drug Congress [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5691,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-17T13:05:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:19:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024\",\"datePublished\":\"2024-04-17T13:05:18+00:00\",\"dateModified\":\"2025-06-27T16:19:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/\"},\"wordCount\":386,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OrphanDrug2024_2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OrphanDrug2024_2.jpg\",\"datePublished\":\"2024-04-17T13:05:18+00:00\",\"dateModified\":\"2025-06-27T16:19:59+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OrphanDrug2024_2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OrphanDrug2024_2.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/17\\\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en el Congreso Mundial de Medicamentos Hu\u00e9rfanos 2024 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-04-17T13:05:18+00:00","article_modified_time":"2025-06-27T16:19:59+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024","datePublished":"2024-04-17T13:05:18+00:00","dateModified":"2025-06-27T16:19:59+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/"},"wordCount":386,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/","url":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en el Congreso Mundial de Medicamentos Hu\u00e9rfanos 2024 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg","datePublished":"2024-04-17T13:05:18+00:00","dateModified":"2025-06-27T16:19:59+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OrphanDrug2024_2.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/17\/nanoscope-therapeutics-to-present-at-the-world-orphan-drug-congress-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5688"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5688\/revisions"}],"predecessor-version":[{"id":9050,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5688\/revisions\/9050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5691"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}